Detail akcie Praxis Precis Rg online

Business Summary: Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Praxis Precision Medicines Inc revenues decreased from $1.1M to $0K. Net loss increased 73% to $214.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects PHARMACEUTICAL segment loss increase of 68% to $229.2M. Basic Earnings per Share excluding Extraordinary Items decreased from -$7.33 to -$9.97.